Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
ConclusionsA single dose of rimegepant 75 mg rimegepant was effective for the acute treatment of migraine in adults living in China, with safety and tolerability similar to placebo.Trial registration Clinicaltrials.gov NCT04574362 Date registered: 2020-10-05.Graphical Abstract
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
More News: China Health | Clinical Trials | Electrocardiogram | Genetics | Headache | Laboratory Medicine | Liver | Migraine | Neurology | Pain | South Korea Health | Study | Urology & Nephrology | USA Health